Aurobindo Pharma has received final approval for sumatriptan succinate tablets 25 mg, 50 mg and 100 mg from US FDA. These tablets are the generic equivalent of GlaxoSmithKline's Imitrex tablets and are indicated for the treatment for acute migraine headaches and falls under the CNS therapeutic segment. The product has been shipped for commercial launch.
The company has total 100 ANDA approvals of which 72 are final and 28 are tentative from US FDA.